Three systems
| System | Definition |
|---|---|
| ISS [1] | I: beta-2 microglobulin below 3.5 mg/L and albumin 3.5 g/dL or more; III: beta-2 microglobulin 5.5 mg/L or more; II: all others |
| R-ISS [2] | I: ISS I with standard-risk cytogenetics and normal LDH; III: ISS III with high-risk cytogenetics (del(17p), t(4;14), t(14;16)) or high LDH; II: all others |
| R2-ISS [3] | Points: ISS II 1, ISS III 1.5, del(17p) 1, high LDH 1, t(4;14) 1, 1q+ 0.5; I: 0, II: 0.5–1, III: 1.5–2.5, IV: 3–5 |
Related cancer types
Treatment regimens (physicians)
Physician tools and lessons
HCT-CI Comorbidity Index Before Stem Cell TransplantationIndications for haematopoietic stem cell transplantation, donor selection and conditioningGraft-versus-host disease (GVHD): prophylaxis, grading and treatmentBone-modifying agents in cancer: bone metastases, adjuvant use and osteonecrosis of the jaw
References
3 referencesShow all referencesClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1International staging system for multiple myeloma
- 2Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- 3Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project
This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/tools/myeloma-r2-iss-calculator/